IL311458A - Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof - Google Patents

Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Info

Publication number
IL311458A
IL311458A IL311458A IL31145824A IL311458A IL 311458 A IL311458 A IL 311458A IL 311458 A IL311458 A IL 311458A IL 31145824 A IL31145824 A IL 31145824A IL 311458 A IL311458 A IL 311458A
Authority
IL
Israel
Prior art keywords
rnr
inhibitors
ribonucleotide reductase
cyclic sulfonamide
sulfonamide
Prior art date
Application number
IL311458A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of IL311458A publication Critical patent/IL311458A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL311458A 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof IL311458A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
IL311458A true IL311458A (en) 2024-05-01

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311458A IL311458A (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Country Status (11)

Country Link
US (1) US20250002486A1 (https=)
EP (1) EP4401728A4 (https=)
JP (1) JP2024534420A (https=)
KR (1) KR20240101555A (https=)
CN (1) CN118434417A (https=)
AU (1) AU2022345092A1 (https=)
CA (1) CA3231660A1 (https=)
IL (1) IL311458A (https=)
MX (1) MX2024003258A (https=)
TW (1) TW202328121A (https=)
WO (1) WO2023043923A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187760A1 (en) 2020-08-12 2022-02-17 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
US20260085067A1 (en) * 2022-09-13 2026-03-26 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
WO2025049814A2 (en) * 2023-09-01 2025-03-06 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067028T2 (hu) * 2016-05-31 2024-09-28 Taiho Pharmaceutical Co Ltd Ribonukleotid reduktáz inhibitor szulfonamid vegyületek vagy sóik rák kezelésére
ES2969901T3 (es) * 2017-11-29 2024-05-23 Taiho Pharmaceutical Co Ltd Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores
MA51228A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
US20220226291A1 (en) * 2019-05-29 2022-07-21 Taiho Pharmaceutical Co., Ltd. Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator
WO2022187200A1 (en) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Also Published As

Publication number Publication date
TW202328121A (zh) 2023-07-16
EP4401728A1 (en) 2024-07-24
MX2024003258A (es) 2024-04-05
JP2024534420A (ja) 2024-09-20
EP4401728A4 (en) 2025-08-06
WO2023043923A1 (en) 2023-03-23
CN118434417A (zh) 2024-08-02
KR20240101555A (ko) 2024-07-02
AU2022345092A1 (en) 2024-04-04
CA3231660A1 (en) 2023-03-23
US20250002486A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
IL311458A (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4322945A4 (en) KRAS G12C INHIBITORS
EP3972978A4 (en) KRAS G12C INHIBITORS AND THEIR USES
EP4192585A4 (en) Kras g12d inhibitors
EP4182313A4 (en) KRAS-G12D INHIBITORS
EP4240489A4 (en) KRAS-G12D INHIBITORS
EP4294290A4 (en) THROMBECTOMY DEVICES
EP3870579A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP4232425A4 (en) Ctps1 inhibitors and uses thereof
EP3866789A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3886843A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3938369A4 (en) TYK2 INHIBITORS AND USES THEREOF
IL312076A (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
EP3914357A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP4443031A4 (en) ELECTRONIC EXPANSION VALVE
EP4301735A4 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
JP1710825S (ja) モバイルコンピュータ
EP4307006A4 (en) DETECTION METHOD AND APPARATUS, AND LASER RADAR
EP4244210A4 (en) Dichlorophenol hsd17b13 inhibitors and uses thereof
EP4452934A4 (en) IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED FROM THESE
EP4192836A4 (en) ATR INHIBITORS AND THEIR USES
EP4165738C0 (en) LASER FIGURE 8
IL310931A (en) 6-aza-quinoline derivatives and related uses
EP4337673C0 (en) PSD-95 INHIBITORS AND RELATED USES
EP4221003A4 (en) TIME INTERVAL CROSS PATH CONFIGURATION METHOD, COMPUTER DEVICE, AND COMPUTER READABLE MEDIUM